Skip to main content
. 2010 Oct 12;29(1):11–16. doi: 10.1200/JCO.2010.30.0855

Fig A2.

Fig A2.

Disease-free survival (DFS) adjusted for possible bias in time to imaging. Overall DFS for patients treated with mFF6 (mFOLFOX6) alone for 6 months or mFF6 for 6 months plus bevacizumab (mFF6 + Bev) for 12 months after correction for the potential bias in time to first imaging because of the differences in treatment duration. Unadjusted Bev results plotted for reference. HR, hazard ratio.